Companies /Healthcare
Boston Scientific Corp
NYSE: BSX Medical Devices
$44.32
▲ $2.34 (+5.57%) today
Markets closed · 9:49pm ET

Boston Scientific (BSX) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+4.13%
Avg. EPS surprise
Consecutive EPS beats
BSX vs Market · 30-day return after each reportBSXS&P 500
−12%−6%0%+6%+5.6%+8.2%Q1 25−1.5%+1.8%Q2 25−6.7%−1.3%Q3 25−4.8%−1.2%Q4 25−10.9%+4.8%Q1 26+1.7%+5.5%Q2 26
−12%−6%0%+6%Q1 25Q3 25Q1 26
BSX EPS Trend · estimate vs actualEstimateActual
$0.00$0.30$0.60$0.90$0.67$0.75Q1 25$0.73$0.75Q2 25$0.71$0.75Q3 25$0.78$0.80Q4 25$0.79$0.80Q1 26$0.83$0.86Q2 26$0.72$0.73Q3 26
$0.00$0.30$0.60$0.90Q1 25Q3 25Q1 26Q3 26
BSX Revenue Trend · estimate vs actualEstimateActual
$0$2.0B$4.0B$4.6B$4.7BQ1 25$4.9B$5.1BQ2 25$5.0B$5.1BQ3 25$5.3B$5.3BQ4 25$5.2B$5.2BQ1 26$5.4B$5.4BQ2 26$5.1B$5.1BQ3 26
$0$2.0B$4.0BQ1 25Q3 25Q1 26Q3 26

How Often Does Boston Scientific Beat Earnings Estimates?

Boston Scientific beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

BSX quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Adjusted EPS of $0.73 excludes $0.14/share amortization expense, $0.02/share goodwill and intangible asset impairment charges, $0.04/share acquisition/divestiture-related net charges, $0.05/share restructuring and restructuring-related net charges, $0.04/share litigation-related net charges, $0.05/share deferred tax expenses, and other items $0.73 est. $0.72 +0.94% $5.1B est. $5.1B +1.66%
Q2 2026 $0.86 est. $0.83 +3.86% $5.4B est. $5.4B +1.42%
Q1 2026 $0.80 est. $0.79 +1.27% $5.2B est. $5.2B +0.60%
Q4 2025 $0.80 est. $0.78 +2.56% $5.3B est. $5.3B +0.04%
Q3 2025 $0.75 est. $0.71 +5.63% $5.1B est. $5.0B +1.83%
Q2 2025 $0.75 est. $0.73 +2.74% $5.1B est. $4.9B +3.39%
Q1 2025 $0.75 est. $0.67 +11.94% $4.7B est. $4.6B +1.98%

Figures from SEC filings and company reports. Not investment advice.